Ladasten® is a derivative of adamantane that positively affects the performance of physical and mental performance. In the spectrum of the drug, activating, anxiolytic, immunostimulating actions and elements of actoprotective activity are combined. Ladasten® lacks hypnose-sedative and muscle relaxant properties, the drug has no addictive potential. When applied, unlike the action of typical psychostimulants, the phenomena of hyperstimulation, as well as aftereffects in the form of depletion of the functional capabilities of the organism, practically do not develop.
The therapeutic effect of Ladasten® in patients with asthenic and anxiety-asthma disorders is manifested with the firstdays of its application in the form of a clear reduction of asthenic symptoms, indicators of emotional stress, somatovegetative manifestations; the drug helps to restore activity and increase endurance.
Mechanism of action Ladastena® is associated with increased release of dopamine from presynaptic terminals, blockade of its re-uptake, and enhanced biosynthesis due to the expression of the tyrosine hydroxylase gene, as well as its modulating effect on the GABA-benzodiazepine-chloroform-form receptor complex, which eliminates the decrease in benzodiazepine receptor that develops under stress. Ladasten® enhances GABA-ergic mediation, reducing the expression of the gene controlling the synthesis of GABA-transporter, which performs a reverse capture of the mediator.
Ladasten® is non-toxic (LD50 in rats exceeds 10,000 mg / kg and more than 100 times greater than effective doses).